<p>Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study</p>-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study

Published:2019-01 Issue: Volume:Volume 12 Page:43-58
ISSN:1178-6965
Container-title:Journal of Asthma and Allergy
language:en
Short-container-title:JAA

Author:

LLanos Jean-Pierre^ORCID,Bell Christopher F,Packnett Elizabeth,Thiel Ellen,Irwin Debra E,Hahn Beth^ORCID,Ortega Hector

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness of dupilumab versus benralizumab and mepolizumab;Allergy and Asthma Proceedings;2024-07-01

2. GEMA 5.3. Spanish Guideline on the Management of Asthma;Open Respiratory Archives;2023-10

3. Economic evaluation of biological treatments in patients with severe asthma: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2023-06-09

4. Biological therapy management from the initial selection of biologics to switching between biologics in severe asthma;Tuberk Toraks;2023-03-10

5. Pharmacologic Management Strategies of Asthma-Chronic Obstructive Pulmonary Disease Overlap;Immunology and Allergy Clinics of North America;2022-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP